Select Publications
Fenaux P et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study. Proc ASH 2007;Abstract 817.
Halpern R et al. Relationship between compliance with imatinib mesylate and medical costs for patients with CML and GIST. Proc ASCO 2007;Abstract 6618.
Kantarjian HM et al. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. Proc ASCO 2008;Abstract 7010.
Knauf WU et al. Bendamustine versus chlorambucil in treatment-naive patients with B-Cell chronic lymphocytic leukemia (B-CLL): Results of an International phase III study. Proc ASH 2007;Abstract 2043.
List AF et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. Proc ASCO 2008;Abstract 7006.
List A et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456-65. Abstract
Mauro MJ et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (STARTC). Proc ASCO 2008;Abstract 7009.
Pye SM et al. The effects of imatinib on pregnancy outcome. Blood 2008;111(12):5505-8. Abstract
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Bruce D Cheson, MD
- Select publications
Hagop M Kantarjian, MD
- Select publications
Sagar Lonial, MD
- Select publications
